Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SOD1 | P00441 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471042 | 0.86 | CA1 (0.44) | CA1CA2ACHEOPRK1SOD1 | |
| SCHEMBL2439590 | 0.84 | DRD2 (0.41) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL7399411 | 0.73 | CA1 (0.64) | CA1CA2ACHEESR2OPRK1 | |
| SCHEMBL565044 | 0.70 | ESR2 (0.42) | ESR2NR1H2DRD2MAPK1 | |
| SCHEMBL9134300 | 0.70 | DRD2 (0.47) | CA1CA2ACHEESR2OPRK1 | |
| SCHEMBL2480740 | 0.70 | NQO2 (0.37) | ESR2GAAMEN1CYP3A4KMT2A | |
| SCHEMBL9136687 | 0.68 | CA1 (0.64) | CA1CA2ACHEESR2DRD2 | |
| SCHEMBL5722246 | 0.68 | CA1 (0.64) | CA1CA2ACHEESR2DRD2 | |
| SCHEMBL5677299 | 0.68 | CA1 (0.64) | CA1CA2ACHEESR2DRD2 | |
| SCHEMBL8768742 | 0.68 | OPRM1 (0.54) | CA1CA2ACHEESR2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-01-04 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2364089-B1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9181191-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2015-08-20 | — | — | US | disclosed |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2014-04-10 | — | — | US | disclosed |
| US-8349849-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2364089-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2010051031-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | CA1 4768/4885CA2 4538/4885ACHE 4858/4885 |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | CA1 4768/4885CA2 4538/4885ACHE 4858/4885 |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | CA1 4768/4885CA2 4538/4885ACHE 4858/4885 |
| US-20100160357-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | CA1 4768/4885CA2 4538/4885ACHE 4858/4885 |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | CA1 4768/4885CA2 4538/4885ACHE 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.